Perioperative N-acetylcysteine: evidence and indications.
Phillip Ryan WilsonKathryn H BridgesMichael D ScofieldSylvia H WilsonPublished in: Pain management (2024)
Nonopioid analgesics serve to improve analgesia and limit side effects and risks of perioperative opioids. N-acetylcysteine (NAC), the primary treatment of acetaminophen toxicity, may have perioperative indications, including analgesia. NAC impacts glutathione synthesis, oxidant scavenging, glutamate receptor modulation and neuroinflammation. Potential perioperative benefits include arrhythmia prevention after cardiac surgery, decreased contrast-induced nephropathy, improved post-transplant liver function and superior pulmonary outcomes with general anesthesia. NAC may improve perioperative analgesia, with some studies displaying a reduction in postoperative opioid use. NAC is generally well tolerated with an established safety profile. NAC administration may predispose to gastrointestinal effects, while parenteral administration may carry a risk of anaphylactoid reactions, including bronchospasm. Larger randomized trials may clarify the impact of NAC on perioperative analgesic outcomes.
Keyphrases
- transcription factor
- patients undergoing
- cardiac surgery
- pain management
- genome wide analysis
- ultrasound guided
- magnetic resonance
- acute kidney injury
- chronic pain
- pulmonary hypertension
- type diabetes
- traumatic brain injury
- computed tomography
- metabolic syndrome
- human health
- neuropathic pain
- diabetic rats
- lps induced
- cognitive impairment
- drug induced
- liver injury
- contrast enhanced
- atrial fibrillation